deltatrials
Active Not Recruiting PHASE1/PHASE2 INTERVENTIONAL 6-arm NCT04123626

A Study to Evaluate the Safety and Tolerability of QR-1123 in Subjects With Autosomal Dominant Retinitis Pigmentosa Due to the P23H Mutation in the RHO Gene (AURORA)

A Prospective First-In-Human Study to Evaluate the Safety and Tolerability of QR-1123 in Subjects With Autosomal Dominant Retinitis Pigmentosa (adRP) Due to the P23H Mutation in the RHO Gene

Sponsor: ProQR Therapeutics

Conditions Autosomal Dominant Retinitis Pigmentosa Eye Diseases Eye Diseases, Hereditary Retinal Disease Retinal Dystrophies Retinitis Vision Disorders Vision Tunnel
Interventions QR-1123 Sham procedure
Updated 14 times since 2019 Last updated: May 5, 2022 Started: Oct 7, 2019 Primary completion: Jun 7, 2022 Completion: Jun 7, 2022
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE1/PHASE2 trial investigates Autosomal Dominant Retinitis Pigmentosa and Eye Diseases and is currently ongoing. ProQR Therapeutics leads this study, which shows 14 recorded versions since 2019 — indicating substantial longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

~Nov 2019 – ~Dec 2019 · 30 days · monthly snapshot~Dec 2019 – ~Jan 2020 · 31 days · monthly snapshot~Jan 2020 – ~Feb 2020 · 31 days · monthly snapshot~Feb 2020 – ~Mar 2020 · 29 days · monthly snapshot~Mar 2020 – ~Jun 2020 · 3 months · monthly snapshot~Jun 2020 – ~Jul 2020 · 30 days · monthly snapshot~Jul 2020 – ~Oct 2020 · 3 months · monthly snapshot~Oct 2020 – ~Jan 2021 · 3 months · monthly snapshot~Jan 2021 – ~Jun 2021 · 5 months · monthly snapshot~Jun 2021 – ~May 2022 · 11 months · monthly snapshot~May 2022 – ~Jun 2022 · 31 days · monthly snapshot~Jun 2022 – ~Jul 2024 · 25 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – present · 22 months · monthly snapshot

Change History

14 versions recorded

  1. Sep 2024 — Present [monthly]

    Active Not Recruiting PHASE1/PHASE2

  2. Jul 2024 — Sep 2024 [monthly]

    Active Not Recruiting PHASE1/PHASE2

    Phase: PHASE1_PHASE2 → PHASE1/PHASE2

  3. Jun 2022 — Jul 2024 [monthly]

    Active Not Recruiting PHASE1_PHASE2

    Status: Recruiting → Active Not Recruiting

  4. May 2022 — Jun 2022 [monthly]

    Recruiting PHASE1_PHASE2

  5. Jun 2021 — May 2022 [monthly]

    Recruiting PHASE1_PHASE2

▶ Show 9 earlier versions

  1. Jan 2021 — Jun 2021 [monthly]

    Recruiting PHASE1_PHASE2

  2. Oct 2020 — Jan 2021 [monthly]

    Recruiting PHASE1_PHASE2

  3. Jul 2020 — Oct 2020 [monthly]

    Recruiting PHASE1_PHASE2

  4. Jun 2020 — Jul 2020 [monthly]

    Recruiting PHASE1_PHASE2

  5. Mar 2020 — Jun 2020 [monthly]

    Recruiting PHASE1_PHASE2

  6. Feb 2020 — Mar 2020 [monthly]

    Recruiting PHASE1_PHASE2

  7. Jan 2020 — Feb 2020 [monthly]

    Recruiting PHASE1_PHASE2

  8. Dec 2019 — Jan 2020 [monthly]

    Recruiting PHASE1_PHASE2

  9. Nov 2019 — Dec 2019 [monthly]

    Recruiting PHASE1_PHASE2

    First recorded

Oct 2019

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • ProQR Therapeutics
Data source: ProQR Therapeutics

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations